Edelris

EDELRIS is a pioneering company dedicated to the design and chemical synthesis of innovative natural product-like screening Libraries, medicinal chemistry Hit-to-Lead / Lead Optimization projects, Custom Synthesis, and Affinity screening-Mass Spectrometry (AS-MS). Aiming at the acceleration of the lead discovery and optimization process in pharma and biotech research organizations, EDELRIS uses its recognized chemistry and screening expertise in drug discovery to provide novelty to its clients and partners. Our unique and first-in-class NP-like, easily tractable screening libraries (Fragments, Covalent binders, conventional HTS & DEL) now contain +2M in-house synthesized compounds, with built-in hit-to-lead optimization capabilities. Our clients can review these libraries on an exclusive or non-exclusive basis. EDELRIS has a wide range of services and provides state-of-the-art target qualification (protein and RNA), screening, and hit identification capacities by applying our in-house AS-MS (Affinity Selection – Mass Spectrometry) technologies. We have a comprehensive chemical analysis department to support our broad portfolio of ongoing organic and medicinal chemistry projects, as well as screening campaigns. The EDELRIS team is capable of delivering innovative solutions to synthetic and medicinal chemistry challenges faced by our clients. When partnering with EDELRIS, we focus our efforts on creating value for your projects. In 2024, Edelris was integrated into the global Janvier Group Biosciences, expanding its capabilities and reach in the drug discovery field